MCID: SPN021
MIFTS: 43

Spinal Meningioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Spinal Meningioma

MalaCards integrated aliases for Spinal Meningioma:

Name: Spinal Meningioma 11 19 14 71
Meningioma, Benign, No Icd-O Subtype 71
Spinal Cord Meningioma 11
Meningioma, Spine 19
Meningioma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:1138
MeSH 43 D008579
NCIt 49 C6935
SNOMED-CT 68 189167009
UMLS 71 C0025286 C0347515 C1762616

Summaries for Spinal Meningioma

GARD: 19 Spinal meningioma is a rare type of spinal cord cancer. The spinal cord is part of the central nervous system. This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors (metastatic), and are typically slow growing. Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). The only proven risk factor in the development of meningioma is exposure to ionizing radiation. Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma.

MalaCards based summary: Spinal Meningioma, also known as meningioma, benign, no icd-o subtype, is related to psammomatous meningioma and neurilemmoma. An important gene associated with Spinal Meningioma is SMARCE1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1), and among its related pathways/superpathways are Assembly of the pre-replicative complex and Chromatin organization. The drugs Thrombin and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and pituitary, and related phenotypes are Increased proliferation and normal

Related Diseases for Spinal Meningioma

Diseases related to Spinal Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 psammomatous meningioma 30.7 TRAF7 PGR NF2
2 neurilemmoma 30.4 SMARCB1 NF2 NF1 LZTR1
3 neurofibromatosis 30.3 SMARCB1 NF2 NF1 LZTR1
4 acoustic neuroma 30.2 SMARCB1 NF2 NF1 LZTR1
5 intraventricular meningioma 30.0 TRAF7 SMARCE1 NF2
6 meningioma, familial 29.9 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
7 neurofibromatosis, type ii 29.8 TRAF7 SMARCB1 NF2 NF1 LZTR1 EPB41
8 meningothelial meningioma 29.7 TRAF7 SMARCE1 SMARCB1 PGR NF2 KLF4
9 benign meningioma 29.6 TRAF7 PGR NF2 KLF4
10 spinal cancer 29.6 TRAF7 SMARCE1 SMARCB1 NF2 NF1 LZTR1
11 microcystic meningioma 29.6 TRAF7 SMARCE1 NF2 MIB1
12 fibrous meningioma 29.0 TRAF7 SMARCE1 SMARCB1 PGR NF2 KLF4
13 intracranial meningioma 28.9 TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
14 transitional meningioma 28.8 TRAF7 SMARCE1 SMARCB1 PGR NF2 KLF4
15 spinal canal and spinal cord meningioma 28.3 TRAF7 SMARCE1 SMARCC2 SMARCB1 PHF10 PGR
16 thoracic spinal canal and spinal cord meningioma 11.3
17 lumbar spinal canal and spinal cord meningioma 11.3
18 multiple spinal canal and spinal cord meningioma 11.3
19 cervical spinal canal and spinal cord meningioma 11.3
20 sacral spinal canal and spinal cord meningioma 11.3
21 cerebellopontine angle meningioma 10.3 SMARCE1 NF2
22 posterior pituitary gland neoplasm 10.3 SMARCB1 NF2
23 pineal region meningioma 10.3 SMARCB1 NF2
24 foramen magnum meningioma 10.3 TRAF7 NF2
25 schwannomatosis 1 10.3 SMARCB1 NF2
26 lung meningioma 10.3 PGR NF2
27 cerebellopontine angle tumor 10.3 SMARCB1 NF2
28 intraneural perineurioma 10.3 TRAF7 NF2
29 petroclival meningioma 10.3 TRAF7 NF2
30 spinal cord disease 10.3
31 paraplegia 10.3
32 melanotic neurilemmoma 10.3 SMARCB1 NF2
33 spinal cord ependymoma 10.2 SMARCB1 NF2
34 epithelioid neurofibroma 10.2 NF2 NF1
35 sphenoorbital meningioma 10.2 TRAF7 SMARCE1 NF2
36 optic nerve astrocytoma 10.2 SMARCB1 NF1
37 cavernous sinus meningioma 10.2 TRAF7 SMARCE1 NF2
38 kidney rhabdoid cancer 10.2 SMARCC2 SMARCB1
39 neurilemmoma of the fifth cranial nerve 10.2 NF2 NF1
40 small intestine leiomyoma 10.2 NF2 NF1
41 trigeminal nerve neoplasm 10.2 NF2 NF1
42 full schwannomatosis 10.2 SMARCB1 NF2 LZTR1
43 anaplastic ependymoma 10.2 SMARCB1 NF2
44 solitary fibrous tumor/hemangiopericytoma 10.2 TRAF7 SMARCE1 SMARCB1
45 spinal cord astrocytoma 10.2 NF2 NF1
46 epidural spinal canal neoplasm 10.2 NF2 NF1
47 petrous apex meningioma 10.2 NF2 EPB41
48 orbital cancer 10.2 NF2 NF1
49 epithelioid malignant peripheral nerve sheath tumor 10.2 SMARCB1 NF1
50 rete ovarii adenoma 10.2 NF2 NF1

Graphical network of the top 20 diseases related to Spinal Meningioma:



Diseases related to Spinal Meningioma

Symptoms & Phenotypes for Spinal Meningioma

GenomeRNAi Phenotypes related to Spinal Meningioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.09 ARID1A BCL7B EPB41 FAT2 KLF4 LZTR1
2 no effect GR00402-S-2 10.09 ARID1A BCL7B EPB41 KLF4 MIB1 NF1
3 Increased proliferation GR00094-A 8.96 NF2 SMARCB1

MGI Mouse Phenotypes related to Spinal Meningioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.97 ARID1A BCL7B FAT2 KLF4 MIB1 NF1
2 embryo MP:0005380 9.86 ARID1A MIB1 NF1 NF2 PBRM1 PGR
3 neoplasm MP:0002006 9.85 ARID1A KLF4 NF1 NF2 PGR SMARCB1
4 craniofacial MP:0005382 9.63 ARID1A KLF4 LZTR1 MIB1 NF1 NF2
5 cardiovascular system MP:0005385 9.61 ARID1A KLF4 LZTR1 MIB1 NF1 PBRM1
6 mortality/aging MP:0010768 9.47 ARID1A BCL7B EPB41 KLF4 LZTR1 MIB1

Drugs & Therapeutics for Spinal Meningioma

Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic acid Approved Phase 4 1197-18-8 5526
3
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Prilocaine Approved Phase 4 721-50-6 4906
6 Fibrin Tissue Adhesive Phase 4
7 Antifibrinolytic Agents Phase 4
8 Hemostatics Phase 4
9 Coagulants Phase 4
10 Anesthetics, Local Phase 4
11 Anesthetics Phase 4
12 Vasoconstrictor Agents Phase 4
13 Epinephryl borate Phase 4
14 Bronchodilator Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Respiratory System Agents Phase 4
22 Mydriatics Phase 4
23 Sympathomimetics Phase 4
24
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
25
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
26
Cisatracurium Approved, Investigational Phase 3 96946-41-7 62887
27
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
28
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Aminolevulinic acid Approved Phase 3 106-60-5 137
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 glucocorticoids Phase 3
35 Contraceptives, Postcoital Phase 3
36 Contraceptives, Oral Phase 3
37 Contraceptive Agents Phase 3
38 Progestins Phase 3
39 Antihypertensive Agents Phase 3
40 Photosensitizing Agents Phase 3
41 Dermatologic Agents Phase 3
42
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
43
Aldesleukin Approved Phase 2 110942-02-4
44
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Hydroxyurea Approved Phase 2 127-07-1 3657
47
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
48
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
49
Verapamil Approved Phase 2 152-11-4, 52-53-9 2520
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
13 A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas Recruiting NCT05130866 Phase 2, Phase 3 REC-2282;Placebo
14 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
15 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Unknown status NCT03016091 Phase 2 Pembrolizumab
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
18 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
19 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
20 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
21 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
22 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
23 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
24 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
25 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
26 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
27 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
30 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
31 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
32 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
35 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
36 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
37 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
38 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
39 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
40 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
41 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
42 Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations Recruiting NCT02523014 Phase 2 Vismodegib;FAK Inhibitor GSK2256098;Capivasertib;Abemaciclib
43 SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Recruiting NCT04298541 Phase 2 Ga-68- DOTATATE;Ga-68-DOTATOC
44 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
45 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
46 An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma Recruiting NCT05023018 Phase 2 NEO100
47 A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma Recruiting NCT05425004 Phase 2 Cabozantinib
48 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
49 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
50 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab

Search NIH Clinical Center for Spinal Meningioma

Genetic Tests for Spinal Meningioma

Anatomical Context for Spinal Meningioma

Organs/tissues related to Spinal Meningioma:

MalaCards : Spinal Cord, Brain, Pituitary, Lymph Node, Breast, Thymus, Bone

Publications for Spinal Meningioma

Articles related to Spinal Meningioma:

(show top 50) (show all 332)
# Title Authors PMID Year
1
Novel use of nonpenetrating titanium clips for pediatric primary spinal dural closure: A technical note. 62
36084429 2022
2
Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord. 62
35943573 2022
3
Spinal Meningioma Surgery in Octogenarians: Functional Outcomes and Complications over a 2-Year Follow-Up Period. 62
36295641 2022
4
Meningioma systematic reviews and meta-analyses: an assessment of reporting and methodological quality. 62
36263847 2022
5
Spinal Meningioma Surgery through the Ages-Single-Center Experience over Three Decades. 62
36363510 2022
6
Functional Outcome after Spinal Meningioma Surgery. 62
35654108 2022
7
Characteristics of Patients Selected for Surgical Treatment of Spinal Meningioma. 62
35779754 2022
8
Posterior-based resection of spinal meningiomas: an institutional experience of 141 patients with an average of 28 months of follow-up. 62
36152326 2022
9
Surgical Treatment of Spinal Meningiomas in the Elderly (≥75 Years): Which Factors Affect the Neurological Outcome? An International Multicentric Study of 72 Cases. 62
36230713 2022
10
Delayed complications of intradural cement leakage after percutaneous vertebroplasty: A case report. 62
36157648 2022
11
Functional Outcome in Spinal Meningioma Surgery and Use of Intraoperative Neurophysiological Monitoring. 62
36010979 2022
12
Clipping Test of a Radiculomedullary Artery During Resection of a Dorsal Spinal Meningioma. 62
35562039 2022
13
Spinal Meningioma in Adults: Imaging Characteristics, Surgical Outcomes, and Risk Factors for Recurrence. 62
35605940 2022
14
Extradural Spinal Lymphoplasmacyte-Rich Meningioma in the Thoracic Spine: A Case Report and Literature Review. 62
36238911 2022
15
Minimally invasive surgery for intradural spinal meningioma: A new standard? A comparative study between minimally invasive and open approaches. 62
35123987 2022
16
Extradural Spinal Meningioma Mimicking a Schwannoma: Magnetic Resonance Imaging Findings. 62
34075867 2022
17
Surgical Resection of Dorsal Spinal Meningiomas with the Inner Dura Layer-An Improved Preservation Technique of Spinal Dura in 40 Cases. 62
34999010 2022
18
Five-year cause-specific survival after meningioma surgery. A nationwide population-based study. 62
34906556 2022
19
Presentation and management of spinal meningioma and its association with breast carcinoma-case series and systematic review. 62
35435093 2022
20
Functional Outcome After Spinal Meningioma Surgery. A Nationwide Population-Based Study. 62
35378584 2022
21
Recovery Potential of Spinal Meningioma Patients With Preoperative Loss of Walking Ability Following Surgery - A Retrospective Single-Center Study. 62
35038831 2022
22
Incidental Spinal Meningioma on an 18F-Fluciclovine PET/CT. 62
35025777 2022
23
Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Location-From Convexity to Skull Base and Spine. 62
35205781 2022
24
The impact of body mass index and height on risk for primary tumours of the spinal cord, spinal meninges, spinal and peripheral nerves in 1.7 million norwegian women and men: a prospective cohort study. 62
35001805 2022
25
Spinal meningiomas in pediatric patients - A case series and literature review. 62
36324961 2022
26
Epidemiology and Survival after Spinal Meningioma Surgery: A Nationwide Population-Based Study. 62
35051328 2022
27
Case Report: Upper Thoracic Purely Extradural Spinal Meningioma With Nerve Root Attachment: A Case Report and Literature Review. 62
35784918 2022
28
MAC-spinal meningioma score: A proposal for a quick-to-use scoring sheet of the MIB-1 index in sporadic spinal meningiomas. 62
36091152 2022
29
Multiple ossified spinal meningiomas in the thoracic spine: A case report and literature review. 62
36268212 2022
30
Cervical Spine Inhomogeneously Enhancing Lesion: Avoiding Confirmation Bias. 62
35110934 2022
31
Novel Dural-Splitting Operative Technique for Excision of Ventrally Located Spinal Meningiomas. 62
34601172 2022
32
Correlations Among Consistency, Computed Tomography Values, and Histopathological Subtypes of Spinal Meningioma. 62
34955539 2021
33
Health-Related Quality of Life and Return to Work after Surgery for Spinal Meningioma: A Population-Based Cohort Study. 62
34944991 2021
34
Microsurgical Resection of Radiation-Induced Cervical Spinal Intradural Extramedullary Meningioma: Dural Splitting Resection. 62
34454072 2021
35
Spinal Meningiomas: Influence of Cord Compression and Radiological Features on Preoperative Functional Status and Outcome. 62
34439337 2021
36
Spinal meningioma surgery in the elderly: who can benefit from it? 62
30468359 2021
37
Characteristics of cases with and without calcification in spinal meningiomas. 62
34119267 2021
38
Clinical characteristics and management differences for grade II and III spinal meningiomas. 62
33973145 2021
39
Clinical features and prognostic factors in spinal meningioma surgery from a multicenter study. 62
34079036 2021
40
Functional outcome and morbidity after microsurgical resection of spinal meningiomas. 62
33932928 2021
41
Demographic and socioeconomic disparities of benign and malignant spinal meningiomas in the United States. 62
33068594 2021
42
Paraplegia due to spinal meningioma during the third trimester of pregnancy: case report and literature review. 62
33859165 2021
43
Predictive Value of Heterogeneously Enhanced Magnetic Resonance Imaging Findings With Computed Tomography Evidence of Calcification for Severe Motor Deficits in Spinal Meningioma. 62
33285060 2021
44
Surgical results of the resection of spinal meningioma with the inner layer of dura more than 10 years after surgery. 62
33603112 2021
45
The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases. 62
33536053 2021
46
The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. 62
33444944 2021
47
Heterotopic ossification in psammomatous spinal meningioma: a diagnostic controversy. 62
34093948 2021
48
Thoracic meningioma with ossification: Case report. 62
34754555 2021
49
Age at Diagnosis and Baseline Myelomalacia Sign Predict Functional Outcome After Spinal Meningioma Surgery. 62
34277695 2021
50
Purely extradural spinal meningioma: A case report and literature review. 62
34513194 2021

Variations for Spinal Meningioma

Expression for Spinal Meningioma

Search GEO for disease gene expression data for Spinal Meningioma.

Pathways for Spinal Meningioma

GO Terms for Spinal Meningioma

Cellular components related to Spinal Meningioma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 10.41 SMARCE1 SMARCC2 SMARCB1 PHF10 PGR PBRM1
2 kinetochore GO:0000776 10.18 PBRM1 PHF10 SMARCB1 SMARCC2 SMARCE1
3 nuclear matrix GO:0016363 10.13 SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1
4 nuclear chromosome GO:0000228 9.97 PBRM1 SMARCB1 SMARCE1
5 nBAF complex GO:0071565 9.97 SMARCC2 SMARCB1 ARID1A SMARCE1
6 brahma complex GO:0035060 9.92 SMARCE1 SMARCC2 SMARCB1 ARID1A
7 bBAF complex GO:0140092 9.86 SMARCE1 SMARCC2 SMARCB1 ARID1A
8 RSC-type complex GO:0016586 9.85 PBRM1 PHF10 SMARCB1 SMARCC2 SMARCE1
9 npBAF complex GO:0071564 9.65 SMARCE1 SMARCC2 SMARCB1 PHF10 ARID1A
10 DNA packaging complex GO:0044815 9.58 ARID1A SMARCB1 SMARCC2
11 SWI/SNF superfamily-type complex GO:0070603 9.51 SMARCB1 ARID1A
12 SWI/SNF complex GO:0016514 9.47 SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 BCL7B

Biological processes related to Spinal Meningioma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.49 ARID1A BCL7B KLF4 PBRM1 PGR PHF10
2 chromatin remodeling GO:0006338 10.3 ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
3 nervous system development GO:0007399 10.22 SMARCE1 SMARCC2 SMARCB1 PHF10 ARID1A
4 negative regulation of cell population proliferation GO:0008285 10.21 SMARCB1 PBRM1 NF2 NF1 KLF4
5 positive regulation of myoblast differentiation GO:0045663 10.21 SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 ARID1A
6 positive regulation of cell differentiation GO:0045597 10.21 SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 NF2
7 positive regulation of stem cell population maintenance GO:1902459 10.18 SMARCE1 SMARCB1 PHF10 BCL7B ARID1A
8 positive regulation of T cell differentiation GO:0045582 10.18 ARID1A PBRM1 PHF10 SMARCB1 SMARCC2 SMARCE1
9 regulation of G1/S transition of mitotic cell cycle GO:2000045 10.17 ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
10 nucleosome disassembly GO:0006337 10.1 ARID1A SMARCB1 SMARCC2 SMARCE1
11 positive regulation of double-strand break repair GO:2000781 10.1 ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
12 regulation of mitotic metaphase/anaphase transition GO:0030071 10 SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 BCL7B
13 chromatin organization GO:0006325 9.92 SMARCE1 SMARCC2 SMARCB1 PBRM1 ARID1A
14 negative regulation of Schwann cell proliferation GO:0010626 9.85 NF2 NF1
15 Schwann cell proliferation GO:0014010 9.81 NF2 NF1
16 regulation of nucleotide-excision repair GO:2000819 9.8 ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
17 regulation of G0 to G1 transition GO:0070316 9.47 SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 BCL7B

Molecular functions related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleosomal DNA binding GO:0031492 9.1 SMARCE1 SMARCC2 SMARCB1

Sources for Spinal Meningioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....